Market Access News | pharmaphorum

News

Sanofi may airlift medicines into UK after Brexit

France’s Sanofi has said it may fly supplies of flu vaccine into the UK if Brexit causes travel disruption after the country leaves the EU.

News

Novo prevents Teva's Victoza rival launch until 2023

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

News

Praluent approved to reduce CV risk in Europe

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan

News

Illustration of a nerve cell on a colored background with light effects

Acadia faces US federal probe into Nuplazid marketing

Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents h

News

Vertex CEO hints at 'new ideas' to bring Orkambi to UK patie...

Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.

News

FDA approves Janssen’s ketamine-based nasal antidepressant

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted

Sanofi may airlift medicines into UK after Brexit

Novo prevents Teva's Victoza rival launch until 2023

Praluent approved to reduce CV risk in Europe

Acadia faces US federal probe into Nuplazid marketing

Vertex CEO hints at 'new ideas' to bring Orkambi to UK patie...

FDA approves Janssen’s ketamine-based nasal antidepressant

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks